Compare Organon & Co. Common Stock (OGN) vs Rockwell Automation (ROK) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Rockwell Automation (ROK) trades at $423.42, down 2.43% amid bearish technical signals, though it maintains strong profitability with 34.47% ROE and has beaten earnings estimates for three consecutive quarters. The company shows robust cash flow generation of $1.54B from operations in 2025 and continues to lead in industrial automation with recent partnerships in AI cybersecurity and biotech automation.

While valuation multiples appear elevated with a P/E of 40.48, analyst consensus targets $489.89 offering 16% upside potential. Key risks include cyclical industrial demand and margin pressure, but the company's strategic positioning in digital transformation provides long-term growth catalysts for patient investors.